2008
News
September 18, 2008: Cambridge Healthtech
Institute (CHI) announced the publication of a new book-length report, Obesity
Drug Pipeline: Developing Therapies for a Complex Disease, by Allan
B. Haberman, Ph.D. This new Insight Pharma Report reviews next-generation
obesity drugs, including late-stage development programs as well as selected early-stage
approaches to developing obesity drugs. It also discusses the obesity drug market,
the need for novel drugs that are safe and truly effective, and the challenges
in developing and commercializing such drugs.
For more
information on the report, or to order it, see the CHI
Insight Pharma Reports website.
May 9, 2008:
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length
report, Blood-Brain Barrier: Bridging Options for Drug Discovery and Development,
by Allan B. Haberman, Ph.D. This new Insight Pharma Report reviews novel
technologies designed to enable small and large molecule drugs to efficiently
cross the blood-brain barrier. The inability of most drugs to cross the blood-brain
barrier is a major bottleneck in the development of central nervous system (CNS)
drugs, especially novel drugs aimed at major unmet needs in the CNS area, such
as Alzheimer's disease, Parkinson's disease, ALS, and stroke.
The
report will be of special interest to you if you are involved in the research,
development, licensing, or portfolio management of current and potential CNS therapeutics.
It will also be of interest to you if you are interested in assessing new opportunities
in CNS diseases for your company.
For more information
on the report, or to order it, see the CHI
Insight Pharma Reports website.
January 1,
2008: Genetic Engineering
News published an article by Allan B. Haberman, Ph.D. in its January 1,
2008 edition, entitled "Addressing
Unmet Type 2 Diabetes Needs". This article is based in part on our recent
book-length report, Diabetes
and Its Complications: Strategies to Advance Therapy and Optimize R&D,
published by Cambridge Healthtech Institute (CHI).